Insulet Corporation (PODD)

Insulet Corporation is trading at $145.91, up 4.45% on the session. The 50 day average sits at $153.90 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 41.1, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $140.63 with resistance near $150.89, so that band frames the current range. Average daily movement is roughly $7.63, or about 5.2% of the share price, which is what any stop placement has to allow for. The overall health score of 35 out of 100 combines a trend score of 44, momentum of 23 and a risk score of 36.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.